Literature DB >> 12220871

Teaching old drugs new tricks. Meeting of the Neurodegeneration Drug Screening Consortium, 7-8 April 2002, Washington, DC, USA.

Jill Heemskerk1, Allan J Tobin, Lisa J Bain.   

Abstract

Meeting of the Neurodegeneration Drug Screening Consortium, held on 7-8 April 2002, Washington, DC, USA.

Entities:  

Mesh：

Year:  2002        PMID： 12220871     DOI： 10.1016/s0166-2236(02)02236-1

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN： 0166-2236            Impact factor:   13.837


  33 in total

1.  Drug screening to identify suppressors of GFAP expression.

Authors:  Woosung Cho; Michael Brenner; Noel Peters; Albee Messing
Journal:  Hum Mol Genet       Date:  2010-06-10       Impact factor: 6.150

2.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila.

Authors:  Barbara L Apostol; Alexsey Kazantsev; Simona Raffioni; Katalin Illes; Judit Pallos; Laszlo Bodai; Natalia Slepko; James E Bear; Frank B Gertler; Steven Hersch; David E Housman; J Lawrence Marsh; Leslie Michels Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-01       Impact factor: 11.205

3.  Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis.

Authors:  Radhia Benmohamed; Anthony C Arvanites; Jinho Kim; Robert J Ferrante; Richard B Silverman; Richard I Morimoto; Donald R Kirsch
Journal:  Amyotroph Lateral Scler       Date:  2010-11-12

Review 4.  Better days are coming for Riley-Day patients.

Authors:  F C Luft
Journal:  J Mol Med (Berl)       Date:  2006-12-22       Impact factor: 4.599

5.  Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia.

Authors:  Matthew M Hims; El Chérif Ibrahim; Maire Leyne; James Mull; Lijuan Liu; Conxi Lazaro; Ranjit S Shetty; Sandra Gill; James F Gusella; Robin Reed; Susan A Slaugenhaupt
Journal:  J Mol Med (Berl)       Date:  2007-01-06       Impact factor: 4.599

6.  Induction of heat shock proteins in differentiated human and rodent neurons by celastrol.

Authors:  Ari M Chow; Ian R Brown
Journal:  Cell Stress Chaperones       Date:  2007       Impact factor: 3.667

7.  Funding evidence: the National Institute of Neurological Disorders and Stroke Clinical Trials Program.

Authors:  Bernard Ravina; Scott Janis; Julianna Keleti; John M Marler
Journal:  NeuroRx       Date:  2004-07

8.  Induction of heat shock proteins in differentiated human neuronal cells following co-application of celastrol and arimoclomol.

Authors:  Catherine A S Deane; Ian R Brown
Journal:  Cell Stress Chaperones       Date:  2016-06-08       Impact factor: 3.667

9.  Small molecule activation of adaptive gene expression: tilorone or its analogs are novel potent activators of hypoxia inducible factor-1 that provide prophylaxis against stroke and spinal cord injury.

Authors:  Rajiv R Ratan; Ambreena Siddiq; Leila Aminova; Brett Langley; Stephen McConoughey; Ksenia Karpisheva; Hsin-Hwa Lee; Thomas Carmichael; Harley Kornblum; Giovanni Coppola; Daniel H Geschwind; Ahmet Hoke; Natalya Smirnova; Cameron Rink; Sashwati Roy; Chandan Sen; Michael S Beattie; Ron P Hart; Martin Grumet; Dongming Sun; Robert S Freeman; Gregg L Semenza; Irina Gazaryan
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

10.  Celastrol from 'Thunder God Vine' protects SH-SY5Y cells through the preservation of mitochondrial function and inhibition of p38 MAPK in a rotenone model of Parkinson's disease.

Authors:  Bong-Suk Choi; Hyool Kim; Hyo Jeong Lee; Kumar Sapkota; Se Eun Park; Seung Kim; Sung-Jun Kim
Journal:  Neurochem Res       Date:  2013-11-09       Impact factor: 3.996
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.